NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 200 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 18h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 200 is an oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. It works as a DOPA decarboxylase inhibitor that increases dopamine availability in the brain while extending levodopa's therapeutic window. The fixed-dose combination simplifies dosing for patients requiring moderate-to-high levodopa doses.
$0.151MPart D
LOE ApproachingThis product is approaching loss of exclusivity with modest Part D spending ($151K), indicating a mature, stable franchise with likely declining promotional investment and smaller team allocations.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STALEVO 200 currently shows zero linked job openings, reflecting its mature lifecycle status and impending LOE. Working on this product offers stable but non-growth opportunities focused on market defense, generic preparation, and patient retention rather than launch-phase or rapid expansion roles.
Company
Worked on STALEVO 200 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.